Business Wire

LIVA-HEALTHCARE

4.3.2021 08:02:04 CET | Business Wire | Press release

Share
Liva Healthcare Attracts Top Medical Scientific Leaders to Global Advisory Board

A leading provider of scalable digital health coaching in Europe, Liva Healthcare (“Liva”), launches new Scientific Advisory Board. Liva has attracted some of Europe’s most respected scientific leaders within chronic conditions and behaviour change psychology to join its global Advisory Board. The board will oversee the medical quality of the programmes and conduct the latest scientific research into Liva’s behavioural change model.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005646/en/

Liva is a health tech company that improve the lives of people at risk of, or living with, chronic conditions such as type 2 diabetes, obesity, and cardiovascular diseases by driving positive behavioural change. Liva recently announced a new funding round of EUR 24.5 million with the aim to expand its European operations. The Liva programmes are used by leading players in public healthcare, insurance and life science industries globally.

Through an app, Liva provides personal human coaching programmes to help people manage their condition and develop healthier habits that last. Liva’s combination of scalable health coaching focused on personal human relationships, with an intuitive and user-friendly interface, has proven to drive substantial clinical outcomes, and is particularly effective among traditionally hard to reach socio-economic groups.

Users on the programme living with obesity have an average sustained weight loss of 6,8kg during the first 9 months, 85% of users at high risk of developing type 2 diabetes reduce their HbA1c levels in 6 months, and 44% of users living with type 2 diabetes normalise their HbA1c level and achieve ‘control’ of their condition after 12 months on the programme (HbA1c level gets below 48 mmol/mol (6,5%).

The Advisory Board will be chaired by Liva’s Chief Medical Officer, MD, PhD, Carl J. Brandt, Postdoctoral researcher at the Research Unit for General Practice, University of Southern Denmark.

“We are proud to present a global Advisory Board of this calibre. With this board, Liva has managed to attract some of Europe’s top scientific leaders to oversee the medical and ethical quality of the Liva programmes, give input on study scope and design, and oversee the evidence-based nature of the Liva programmes,” says Dr. Brandt. “We have gathered multiple competences within our therapeutic and technological areas to guide decision-making and ensure science and research is the foundation for everything we do,” adds Dr. Brandt.

Joining Liva’s Advisory Board is Prof. Dr Lisette Van Gemert-Pijnen, Chair of Persuasive Health Technology at university of Twente, and Head of Centre for eHealth & Wellbeing Research.

“In our research at university of Twente and the Centre for eHealth & Wellbeing Research, we study how persuasive health technology can be applied to increase self-management of long-term chronic diseases, like diabetes,” says Prof. Gemert-Pijnen. “Liva Healthcare has demonstrated impressive proven clinical outcomes in chronic disease prevention and management, especially within obesity, prediabetes and type 2 diabetes, and that is why I have decided to join the Advisory Board.”

“I have been conducting research on the Dutch COVID-19 contact tracing app: CoronaMelder, and COVID-19 has taught us the importance of user-friendly, reliable and inclusive digital health tools. Generally, there has been a shift in acceptance of remote healthcare, and the need for credible digital solutions is now greater than ever. Fortunately, the Liva programmes have demonstrated how effective personalised, remote health solutions can be, and I am delighted to take a seat in this highly competent Advisory Board,” adds Prof. Gemert-Pijnen.

Additional Advisory Board members include:

- Prof. Timothy Skinner, Director of University department of Rural Health at La Trobe University, and Professor of Health Psychology at University of Copenhagen. Prof. Skinner has been responsible for developing several diabetes self-management support programmes, including DESMOND, the longest standing NHS training course for people with type 2 diabetes.

- Prof. Thorsten Lewalter, Head of Department of Cardiology, int. Klinikum München Süd, and Director of Department of Cardiology, Peter Osypka Heart Center. Prof. Lewalter is a renowned cardiology expert. He is co-editor of numerous professional journals and is considered one of the founders of modern therapy of cardiac arrhythmias.

- Stephanie Kaiser, Founder and Managing Director of the digital health platform Heartbeat Labs. Kaiser has more than 12 years’ experience in building and developing digital, consumer-oriented products. Since 2018, Kaiser has been a member of the Digital Council that advises the chancellor of Germany and the German government on the important matter of digitalisation.

- Prof. Åke Sjöholm, Associate Professor of Medicine at University of Gävle, Associate Professor at Karolinska Institute, Professor of University of South Alabama, and Associate Professor Diabetes at Region Gävleborg. Prof. Sjöholm is a prominent Swedish diabetes expert and has been listed as a noteworthy diabetes researcher by Marquis Who's Who.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Access Advance Announces New Effective Discount Rates for Its Multi-Codec Bridging Agreement, Starting on January 1, 202711.11.2026 20:18:00 CET | Press release

Access Advance LLC today announced that the Licensors of the HEVC Advance and VVC Advance Patent Pools have independently approved a two-step, phased reduction in the effective royalty discount available under the Multi-Codec Bridging Agreement (MCBA) for Licensees of both pools who sign the MCBA on or after January 1, 2027. Licensees that join both the HEVC Advance and VVC Advance Patent Pools and execute the MCBA on or before December 31, 2026, will secure the current MCBA rates, resulting in an effective discount of up to 50%. Licensees that sign on or after January 1, 2027 will receive a reduced discount as further described below. The MCBA is an administrative agreement, not a separate license, that lets Licensees of both HEVC Advance and VVC Advance Patent Pools pay a single, reduced royalty rate for products that include both HEVC and VVC codecs. Today the MCBA rate for a dual-codec product is the same as the VVC Advance single codec product rate; up to 50% of what a Licensee wo

Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release

Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release

Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath

De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release

The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par

Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release

Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye